Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck Serono launches Ismigen vaccine in Argentina

This article was originally published in Scrip

Executive Summary

Merck Serono has launched Ismigen in Argentina for the prophylaxis and treatment of chronic, subacute and acute respiratory tract infections. The sublingual vaccine, made up of polyvalent bacterial mechanical lysate, is licensed from Lallemand Pharma International. It is now approved for marketing in 12 countries and has been filed in a further 25 countries. A recent Phase II clinical trial of 63 subjects suggests that Ismigen provides a therapeutic benefit to chronic obstructive pulmonary disease (COPD) patients who are already being treated with salmeterol and fluticasone.